Thermo Fisher Scientific Inc. (NYSE:TMO) is one of the 10 best life sciences stocks to buy according to hedge funds.
On January 30, Daniel Arias of Stifel Nicolaus maintained a Buy rating on Thermo Fisher Scientific Inc. (NYSE:TMO), with a $700 price target. The analyst reflected on the company’s strong finish to 2025, highlighting that Thermo Fisher Scientific Inc. (NYSE:TMO) was among the few sector names that did not pre-announce results before delivering a solid Q4 beat.
The company reported revenue growth of 3.91% over the past twelve months, with total revenue reaching $44.56 billion. Management shared guidance of roughly 3–6% organic growth in 2026, initially leaning towards the lower end of the range, indicating a cautious but stable outlook.
On January 30, Catherine Schulte from Baird increased the price target on Thermo Fisher Scientific Inc. (NYSE:TMO) from $645 to $653, maintaining her Outperform rating on the shares. Baird revised its model following the fourth-quarter announcement and continues to view the stock as a top investment idea.
Thermo Fisher Scientific Inc. (NYSE:TMO) facilitates research and diagnostics through high-end life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products. The company also offers software, consumables, pharma, and instrument services to various research and industrial markets. It covers several segments such as academics, biotechnology, government, pharmaceuticals, and others.
While we acknowledge the potential of TMO as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.
READ NEXT: 15 Most Promising Mid-Cap Healthcare Stocks Under $50 and 11 Most Promising Small-Cap Industrial Stocks Under $50.
Disclosure: None. Follow Insider Monkey on Google News.